The FDA has approved lenacapavir as the first injectable pre-exposure prophylaxis for HIV, to be administered every 6 months, designed to target multiple stages of the HIV lifecycle. It showed high efficacy in preventing HIV infection, with minimal side effects and potential to improve prevention outcomes. Lenacapavir may help increase access to PrEP in underserved populations in the US, and assistance programs are in place. It is also approved for the treatment of multidrug-resistant HIV.

Source: GILEAD